The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Gain on lease termination | - | - | - | 10 |
| Deferred tax provision | - | - | - | 431 |
| Net loss and comprehensive loss | -17,459 | -17,711 | - | -36,184 |
| Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds | - | - | - | -30,900 |
| Non-cash lease expense | 79 | 77 | 76 | - |
| Accretion on investment discounts | -251 | -432 | -692 | -2,799 |
| Stock-based compensation | 2,428 | 2,694 | 2,864 | 13,122 |
| Amortization of operating lease right-of-use asset | - | - | - | 359 |
| Change in fair value of warrant liabilities | -564 | -22,353 | - | - |
| Prepaid expenses and other assets | -805 | 989 | -724 | -1,298 |
| Accounts payable, accrued expenses and other liabilities | 566 | 4,523 | -2,403 | 7,751 |
| Operating lease liabilities | -81 | -77 | -74 | -339 |
| Net cash used in operating activities | -14,477 | -17,713 | -16,060 | -47,271 |
| Purchase of available-for-sale short-term investments | 32,655 | 27,404 | 31,850 | 156,131 |
| Proceeds from maturities of available-for-sale short-term investments | 45,060 | 42,362 | 35,742 | 85,817 |
| Net cash provided by (used in) investing activities | 12,405 | 14,958 | 3,892 | -70,314 |
| Proceeds from exercise of stock options | 0 | 0 | 115 | 215 |
| Proceeds from issuances of common stock and pre-funded warrants, net | - | - | - | 133,307 |
| Net cash provided by financing activities | 0 | 0 | 115 | 133,522 |
| Net change in cash and cash equivalents | -2,072 | -2,755 | -12,053 | 15,937 |
| Cash and cash equivalents at beginning of period | 20,549 | - | - | - |
| Cash and cash equivalents at end of period | 3,669 | - | - | - |
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)